Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580873 | 0.85 | KAT6A (0.46) | F10GRIN2BHDAC8TAS1R3TAS1R1 | |
| SCHEMBL1580875 | 0.85 | KAT6A (0.46) | F10GRIN2BHDAC8TAS1R3TAS1R1 | |
| SCHEMBL29478758 | 0.85 | KAT6A (0.46) | F10GRIN2BHDAC8TAS1R3TAS1R1 | |
| SCHEMBL29448761 | 0.78 | PARP1 (0.61) | F10TAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL31322467 | 0.78 | F10 (0.47) | F10GRIN2BHDAC8TAS1R3TAS1R1 | |
| SCHEMBL23062938 | 0.78 | F10 (0.47) | F10GRIN2BHDAC8TAS1R3TAS1R1 | |
| SCHEMBL711132 | 0.78 | PARP1 (0.61) | F10TAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL8810191 | 0.78 | F10 (0.64) | F10PRSS1PRSS2PRSS3 | |
| SCHEMBL16959752 | 0.78 | TAS1R3 (0.48) | F10HDAC8TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14818810 | 0.77 | KAT6A (0.48) | HDAC8TAS1R3TAS1R1TAS1R2KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | SIRT6, SIRT1, SIRT2 | F10 3420/4885GRIN2B 4799/4885HDAC8 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.